SARASOTA, Fla., Oct. 23, 2014 /PRNewswire/ -- Rock Creek
Pharmaceuticals, Inc. (NASDAQ: RCPI), a drug development company
focused on chronic inflammatory disease and neurologic disorders,
announced today that abstracts outlining four separate preclinical
studies evaluating anatabine, the primary constituent in the
Company's lead investigational compound anatabine citrate, have
been accepted for poster and nano symposium presentations at the
upcoming annual meeting of the Society for Neuroscience, taking
place November 15-19 in Washington, DC. This meeting is the
premier event in the field, typically attracting approximately
30,000 attendees, with 15,000 scientific presentations and nearly
600 presenting companies.
The studies were independently conducted by the Roskamp
Institute, a not-for-profit research organization devoted to
understanding causes and finding cures for neuropsychiatric and
neurodegenerative disorders and addictions. The studies were funded
by either the Roskamp Foundation or by awards through the
Congressionally Directed Medical Research Program.
Michael J. Mullan, MBBS (MD),
PhD, Rock Creek Pharmaceuticals' Chairman and CEO, commented, "The
data from the accepted abstracts demonstrates the continued
application of anatabine for beneficial effects in preclinical
mouse models of human diseases."
A list of the abstracts and timing of the presentations is
provided below:
Presentation
title:
|
Beneficial effects
of anatabine in a mouse model of tauopathy
|
Program
#/Poster#:
|
40.07/D32
|
First Presenting
Author:
|
Daniel Paris, Ph.D.,
Roskamp Institute, Sarasota, Florida
|
Presentation
Time:
|
Saturday, November
15, 3:00 PM
|
|
|
Presentation
title:
|
Effects of
anatabine on Alzheimer's disease (AD) like pathology,
neuroinflammation and behavior in transgenic mouse model of
AD
|
Program
#/Poster#:
|
307.17/D63
|
First Presenting
Author:
|
Megha Verma, Ph.D,
Roskamp Institute, Sarasota, Florida
|
Presentation
Time:
|
Monday, November 17,
8:00 AM
|
|
|
Presentation
title:
|
Anatabine
ameliorates cognitive impairment and neuropathological deficits in
a mouse model of Gulf War Illness
|
Program
#/Poster#:
|
423.07/Z2
|
First Presenting
Author:
|
Ghania Ait-Ghezala,
Ph.D., Roskamp Institute, Sarasota, Florida
|
Presentation
Time:
|
Monday, November 17,
1:00 PM
|
|
|
Presentation
title:
|
Delayed treatment
of Anatabine after repetitive mild TBI normalizes spatial memory
impairment
|
Program
#/Poster#:
|
486.92
|
First Presenting
Author:
|
Scott Ferguson,
Ph.D., Roskamp Institute, Sarasota, Florida
|
Presentation
Time:
|
Tuesday, November 18
at 8:15 AM: Nano Symposium
|
About Anatabine Citrate:
Rock Creek Pharmaceuticals' anatabine citrate is a small
molecule, cholinergic agonist, which exhibits anti-inflammatory
pharmacological characteristics. The Company has sponsored
extensive pre-clinical in vitro and in vivo studies resulting in
peer reviewed and scientific journal articles, covering
inflammatory models of Multiple Sclerosis, Alzheimer's Disease, and
Auto-Immune Thyroiditis. In addition, the Company's compilation of
human exposure, safety and tolerability data, provides important
insights for future clinical pathway progression.
About Rock Creek Pharmaceuticals:
Rock Creek Pharmaceuticals, Inc. is an emerging drug development
company focused on the discovery, development and commercialization
of new drugs, formulations and compounds that provide therapies for
chronic inflammatory disease, neurologic disorders and behavioral
health.
For more information, visit: http://www.rockcreekpharma.com
About the Roskamp Institute:
The Roskamp Institute is devoted to understanding causes and
finding cures for neuropsychiatric and neurodegenerative disorders.
The Institute utilizes a broad range of scientific approaches to
understanding the causes of and potential therapies for these
disorders with an emphasis on Alzheimer's disease. The Institute is
located in Sarasota, Florida, and
operates a memory clinic onsite.
For more information, visit: http://www.rfdn.org
CONTACT:
Ted Jenkins
Vice President, Corporate Strategy, Development, Investor
Relations
Rock Creek Pharmaceuticals
2040 Whitfield Avenue, Suite 300
Sarasota, FL 34243
Direct: 941-251-0488
tjenkins@rockcreekpharma.com
Stephanie Carrington/ Bo
Park
Investors/Media
Integrated Corporate Relations, Inc. (ICR): Redefining Strategic
Communications
685 Third Avenue, 2nd
Floor,
New York, NY 10017
(646) 277-1282/(646) 277-1222
stephanie.carrington@icrinc.com
bo.park@icrinc.com
Forward Looking Statements
Certain statements contained in this release constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to statements identified by words such as
"believes," "expects," "anticipates," "estimates," "intends,"
"plans," "targets," "projects" and similar expressions. The
statements in this release are based upon the current beliefs and
expectations of our company's management and are subject to
significant risks and uncertainties. Actual results may differ from
those set forth in the forward-looking statements. Numerous factors
could cause or contribute to such differences, including, but not
limited to, results of clinical trials and/or other studies, the
challenges inherent in new product development initiatives,
including the continued development and approval of
anti-inflammatory drug candidates, the effect of any competitive
products, our ability to license and protect our intellectual
property, our ability to raise additional capital in the future
that is necessary to maintain our business, changes in government
policy and/or regulation, potential litigation by or against us,
any governmental review of our products or practices and the
outcome of the ongoing investigations as well as other risks
discussed from time to time in our filings with the Securities and
Exchange Commission, including, without limitation, our annual
report on Form 10-K for the fiscal year ended December 31, 2013 filed on March 17, 2014 and our latest 10-Q Report filed
on August 11, 2014. We undertake no
duty to update any forward-looking statement or any information
contained in this press release or in other public disclosures at
any time.
Logo -
http://photos.prnewswire.com/prnh/20141023/153937LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rock-creek-pharmaceuticals-announces-presentation-of-four-anatabine-projects-at-neuroscience-2014-788799630.html
SOURCE Rock Creek Pharmaceuticals, Inc.